AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30831541 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg melatonin (2 capsules of 5 mg each) once a day 1 hour before bedtime for 12 weeks
Number of subjects: 58
Study 27864672 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinolight® intranasal phototherapy (combination of UV‐B, UV‐A, and high‐intensity visible light)
Number of subjects: 34
Study 27864672 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (low‐intensity visible white light intranasal phototherapy)
Number of subjects: 34
Study 27864672 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinolight® intranasal phototherapy
Number of subjects: 34
Study 26582137 — intervention group
Group type: EXPERIMENTAL
Intervention: Food advertisement
Number of subjects: 100
Study 26582137 — intervention group
Group type: COMPARATOR
Intervention: Control (toy advertisement)
Number of subjects: 100
Study 24779680 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 250 mg daily
Number of subjects: 1113
Study 23083020 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 400 mg/day
Number of subjects: 220
Study 23083020 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 800 mg/day
Number of subjects: 220
Study 23083020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 23083020 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 220
Study 19930006 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 1.2 mg/metformin
Number of subjects: 0
Study 19930006 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 1.8 mg/metformin
Number of subjects: 0
Study 19930006 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide (monotherapy)
Number of subjects: 0
Study 19930006 — intervention group
Group type: COMPARATOR
Intervention: glimepiride/metformin
Number of subjects: 0
Study 19930006 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 17347011 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 0.1IU/kg/day [0.033mg/kg/day]
Number of subjects: 30
Study 17347011 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 0.2IU/kg/day [0.067mg/kg/day]
Number of subjects: 30
Study 17347011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16426800 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly functional-skills training
Number of subjects: 224
Study 16426800 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of resistance and functional-skills training
Number of subjects: 224
Study 16426800 — intervention group
Group type: COMPARATOR
Intervention: Resistance training
Number of subjects: 224
Study 16426800 — intervention group
Group type: COMPARATOR
Intervention: Control program
Number of subjects: 224
Study 12044130 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative medicine therapies (specifics not provided)
Number of subjects: 0
Study 12044130 — intervention group
Group type: COMPARATOR
Intervention: Placebo effect of unconventional medicine
Number of subjects: 0
Study 9469978 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad lib, low fat, high carbohydrate diet
Number of subjects: 43
Study 9469978 — intervention group
Group type: COMPARATOR
Intervention: Fixed energy diet (< 8 MJ/day)
Number of subjects: 43
Study 7892882 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy
Number of subjects: 118
Study 7892882 — intervention group
Group type: COMPARATOR
Intervention: Dietary calcium augmentation
Number of subjects: 118
Study 7892882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 2576217 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg/kg
Number of subjects: 0
Study 2576217 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.2 mg/kg
Number of subjects: 0
Study 2576217 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.3 mg/kg
Number of subjects: 0
Study 2576217 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.4 mg/kg
Number of subjects: 0
Study 2576217 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 795434 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflucortolone valerate (Nerisona) in cream, ointment, and fatty ointment
Number of subjects: 1923
Study 795434 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflucortolone valerate (Nerisona) ointment
Number of subjects: 1923
Study 795434 — intervention group
Group type: COMPARATOR
Intervention: Commercial preparations (beta‐methasone‐17‐valerate, fluocinonide, fluocinolone acetonide, flumetasone pivalate, desoximetasone)
Number of subjects: 1923
Study 31394404 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0
Study 31394404 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort studies
Number of subjects: 0
Study 31394404 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-control studies
Number of subjects: 0
Study 31394404 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 4 observational studies
Number of subjects: 0
Study 31394404 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled phase 1 studies
Number of subjects: 0
Study 31394404 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient or disease registries
Number of subjects: 0
Study 28333531 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Living Triple P intervention (2 group sessions of 2 hours each)
Number of subjects: 107
Study 28333531 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 107
Study 25368202 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in resting heart rate (HR) from preceding visit
Number of subjects: 7599
Study 25368202 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowering of resting heart rate (HR)
Number of subjects: 7599
Study 25368202 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-updated resting HR at each visit
Number of subjects: 7599
Study 23549824 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at effect-site concentration of 4 ng/mL (group R4)
Number of subjects: 69
Study 23549824 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at effect-site concentration of 2 ng/mL (group R2)
Number of subjects: 69
Study 23549824 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at effect-site concentration of 6 ng/mL (group R6)
Number of subjects: 69
Study 23549824 — intervention group
Group type: COMPARATOR
Intervention: Comparison among groups R2, R4, and R6
Number of subjects: 69
Study 23549824 — intervention group
Group type: EXPERIMENTAL
Intervention: Group R4
Number of subjects: 69
Study 23549824 — intervention group
Group type: EXPERIMENTAL
Intervention: Group R2
Number of subjects: 69
Study 23549824 — intervention group
Group type: EXPERIMENTAL
Intervention: Group R6
Number of subjects: 69
Study 21749461 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted environmental exposure-reducing intervention
Number of subjects: 476
Study 21749461 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 476
Study 19414206 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.6 mmol/l cutoff for impaired fasting glucose
Number of subjects: 5794
Study 19414206 — intervention group
Group type: COMPARATOR
Intervention: 6.1 mmol/l cutoff for impaired fasting glucose
Number of subjects: 5794
Study 19414206 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance and fasting glucose
Number of subjects: 5794
Study 16673249 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant TAC chemotherapy
Number of subjects: 70
Study 15220788 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 ml/h ropivacaine, 0.1% (group R)
Number of subjects: 30
Study 15220788 — intervention group
Group type: COMPARATOR
Intervention: 12 ml/h saline (group N)
Number of subjects: 30
Study 12941031 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral heparin/SNAC (90 000 U heparin)
Number of subjects: 123
Study 12941031 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral heparin/SNAC (60 000 U heparin)
Number of subjects: 123
Study 12941031 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous UFH (5000 U)
Number of subjects: 123
Study 10438403 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone-releasing factor (GRF) 500 microg twice daily
Number of subjects: 196
Study 10438403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 7760609 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha n1 (IFN-alpha)
Number of subjects: 587
Study 7760609 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy with busulphan or hydroxyurea (no IFN-alpha)
Number of subjects: 587
Study 2138703 — intervention group
Group type: EXPERIMENTAL
Intervention: hANP infusion (0.3 micrograms/min)
Number of subjects: 8
Study 2138703 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 8
Study 7438382 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone (200 mg four times a day)
Number of subjects: 1558
Study 7438382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1558
Study 29211236 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacred music with vocals (Group 2)
Number of subjects: 69
Study 29211236 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental sacred music (Group 3)
Number of subjects: 69
Study 29211236 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 69
Study 26288467 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g single supervised dose of azithromycin
Number of subjects: 292
Study 26288467 — intervention group
Group type: COMPARATOR
Intervention: 500 mg azithromycin once daily for 5 days (conventional dose)
Number of subjects: 292
Study 22753403 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint space narrowing (JSN)
Number of subjects: 508
Study 22753403 — intervention group
Group type: EXPERIMENTAL
Intervention: Erosions
Number of subjects: 508
Study 22753403 — intervention group
Group type: EXPERIMENTAL
Intervention: Damage in the wrist
Number of subjects: 508
Study 22753403 — intervention group
Group type: EXPERIMENTAL
Intervention: Erosions in the wrist
Number of subjects: 508
Study 22753403 — intervention group
Group type: EXPERIMENTAL
Intervention: Erosions in the wrist (independently associated)
Number of subjects: 508
Study 22269194 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribbond ribbon + Composite
Number of subjects: 30
Study 22269194 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel wire + Composite
Number of subjects: 30
Study 19178120 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 0
Study 19178120 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational data
Number of subjects: 0
Study 16979581 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based cognitive therapy (CT)
Number of subjects: 210
Study 16979581 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational support groups
Number of subjects: 210
Study 16979581 — intervention group
Group type: COMPARATOR
Intervention: Intensive symptom monitoring
Number of subjects: 210
Study 16979581 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based cognitive therapy (CT) and Psychoeducational support groups
Number of subjects: 210
Study 14984447 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucometer test strips provided free of charge (NC)
Number of subjects: 62
Study 14984447 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) had to purchase strips
Number of subjects: 62
Study 11576817 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard error as the vertical axis in funnel plots
Number of subjects: 78
Study 11576817 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision or inverse of variance as the vertical axis in funnel plots
Number of subjects: 78
Study 11576817 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample size or log sample size as the vertical axis in funnel plots
Number of subjects: 78
Study 11576817 — intervention group
Group type: EXPERIMENTAL
Intervention: Odds ratios or risk ratios on the horizontal axis
Number of subjects: 78
Study 11576817 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk differences on the horizontal axis
Number of subjects: 78
Study 11576817 — intervention group
Group type: EXPERIMENTAL
Intervention: Funnel plots of meta-analyses using standard error as the measure of study size
Number of subjects: 78
Study 9324340 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation
Number of subjects: 62
Study 9324340 — intervention group
Group type: COMPARATOR
Intervention: Intensive chemotherapy
Number of subjects: 62
Study 8182401 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and placebo tablets
Number of subjects: 85
Study 8182401 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 100 mg daily
Number of subjects: 85
Study 29554406 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharyngeal pack placement under videolaryngoscopic guidance (video guidance group)
Number of subjects: 80
Study 29554406 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharyngeal pack placement blindly (blind insertion group)
Number of subjects: 80
Study 29554406 — intervention group
Group type: COMPARATOR
Intervention: No pharyngeal pack (control group)
Number of subjects: 80
Study 27529693 — intervention group
Group type: EXPERIMENTAL
Intervention: Play-based intervention (six clinic play-sessions, weekly home-modules, one-month home follow-up)
Number of subjects: 29
Study 27529693 — intervention group
Group type: COMPARATOR
Intervention: Control (waitlist for 10 weeks)
Number of subjects: 29
Study 27529693 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data from both groups
Number of subjects: 29
Study 24431325 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-sensing receptor-activating amino acids (CaSR-AAAs) L-tryptophan, L-phenylalanine, and L-histidine
Number of subjects: 14
Study 24431325 — intervention group
Group type: EXPERIMENTAL
Intervention: Dibasic amino acids (DAAs) L-arginine and L-lysine
Number of subjects: 14
Study 24431325 — intervention group
Group type: COMPARATOR
Intervention: Control diet (methylcellulose capsules)
Number of subjects: 14
Study 22622073 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (surgical exclusion of the internal carotid artery stump combined with endarterectomy of the external carotid artery)
Number of subjects: 40
Study 22622073 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment
Number of subjects: 40
Study 22622073 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 40
Study 20524190 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive glass (BG) - S53P4
Number of subjects: 21
Study 20524190 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone (AB)
Number of subjects: 21
Study 18024166 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-level positive pressure ventilation (S/T mode)
Number of subjects: 37
Study 18024166 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servo ventilation (AutoSetCS)
Number of subjects: 37
Study 18024166 — intervention group
Group type: COMPARATOR
Intervention: Control investigations after 6 weeks
Number of subjects: 37
Study 16876399 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 942
Study 12826837 — intervention group
Group type: EXPERIMENTAL
Intervention: Colforsin daropate (0.75 microg. kg‐1 x min‐1 intravenously)
Number of subjects: 46
Study 12826837 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 46
Study 11022066 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 109
Study 11022066 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 109
Study 11022066 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 109
Study 8781005 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal culturally specific intervention
Number of subjects: 0
Study 8781005 — intervention group
Group type: COMPARATOR
Intervention: Self-help intervention
Number of subjects: 0
Study 8781005 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention for Baptists
Number of subjects: 0
Study 1452560 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 22
Study 1452560 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 22
Study 3880995 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 376
Study 3880995 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 376
Study 31707827 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 183
Study 31707827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 29950826 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) 36/9.6 µg
Number of subjects: 185
Study 29950826 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) 36/7.2 µg
Number of subjects: 185
Study 29950826 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) 18/9.6 µg
Number of subjects: 185
Study 29950826 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) 9/9.6 µg
Number of subjects: 185
Study 29950826 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrrolate (GP) MDI 36 µg
Number of subjects: 185
Study 29950826 — intervention group
Group type: COMPARATOR
Intervention: Formoterol fumarate (FF) MDI 9.6 µg
Number of subjects: 185
Study 26248047 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (600 mg PO)
Number of subjects: 0
Study 26248047 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol (25 mg PO)
Number of subjects: 0
Study 26248047 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (5 mg/70 kg IV)
Number of subjects: 0
Study 26248047 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine and naloxegol combination
Number of subjects: 0
Study 26248047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25242045 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat, bortezomib, and dexamethasone
Number of subjects: 768
Study 25242045 — intervention group
Group type: COMPARATOR
Intervention: Placebo, bortezomib, and dexamethasone
Number of subjects: 768
Study 22796472 — intervention group
Group type: EXPERIMENTAL
Intervention: aCRT
Number of subjects: 522
Study 22796472 — intervention group
Group type: COMPARATOR
Intervention: Echo
Number of subjects: 522
Study 19606937 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan combination therapy
Number of subjects: 0
Study 19606937 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 0
Study 17626056 — intervention group
Group type: COMPARATOR
Intervention: Combined hormone therapy (conjugated equine oestrogens plus medroxyprogesterone acetate 2.5/5.0 mg orally daily)
Number of subjects: 5692
Study 17626056 — intervention group
Group type: COMPARATOR
Intervention: Combined hormone therapy
Number of subjects: 5692
Study 16307967 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 microg oral misoprostol (single-dose)
Number of subjects: 300
Study 16307967 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 microg oral misoprostol (repeated-dose)
Number of subjects: 300
Study 16307967 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 300
Study 11927189 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 40
Study 11927189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9795070 — intervention group
Group type: EXPERIMENTAL
Intervention: New levodopa/benserazide dual-release formulation (DRF)
Number of subjects: 18
Study 9795070 — intervention group
Group type: COMPARATOR
Intervention: Conventional slow-release formulation (SRF)
Number of subjects: 18
Study 7544670 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 23
Study 7544670 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 23
Study 2496310 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin with HMG
Number of subjects: 44
Study 2496310 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate with HMG
Number of subjects: 44
Study 4898 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐methyldopa
Number of subjects: 24
Study 4898 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol
Number of subjects: 24
Study 4898 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 30830180 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 0
Study 30830180 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 27830967 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (TKIs)
Number of subjects: 1710
Study 27830967 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 1710
Study 25915168 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (375 mg once daily for 2 weeks)
Number of subjects: 18
Study 25915168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 24210844 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive autoinflation device
Number of subjects: 31
Study 24210844 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31
Study 21407132 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate supplementation (NaNO(3) 10 mg·kg(‐1) of body mass)
Number of subjects: 11
Study 19585385 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraprostatic injections with mepivacaine epinephrine
Number of subjects: 85
Study 19585385 — intervention group
Group type: COMPARATOR
Intervention: No intraprostatic injections
Number of subjects: 85
Study 17760598 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% lidocaine and 7% tetracaine (LT) peel
Number of subjects: 0
Study 17760598 — intervention group
Group type: COMPARATOR
Intervention: Placebo or 1:1 eutectic mixture of local anesthetics (EMLA) cream
Number of subjects: 0